Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, ProKidney Corp’s stock clocked out at $0.75, up 2.21% from its previous closing price of $0.73. In other words, the price has increased by $2.21 from its previous closing price. On the day, 1.49 million shares were traded. PROK stock price reached its highest trading level at $0.764 during the session, while it also had its lowest trading level at $0.6574.
Ratios:
To gain a deeper understanding of PROK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.93 and its Current Ratio is at 10.93.
On September 10, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 17 ’25 when Control Empresarial de Capital bought 25,000 shares for $0.75 per share. The transaction valued at 18,690 led to the insider holds 73,455,330 shares of the business.
Control Empresarial de Capital bought 100,000 shares of PROK for $74,820 on Apr 16 ’25. The Add’l Rep. Persons-see Ex.99-1 now owns 73,430,330 shares after completing the transaction at $0.75 per share. On Apr 15 ’25, another insider, Control Empresarial de Capital, who serves as the Add’l Rep. Persons-see Ex.99-1 of the company, bought 468,000 shares for $0.70 each. As a result, the insider paid 326,009 and bolstered with 73,330,330 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PROK now has a Market Capitalization of 1811825792 and an Enterprise Value of 1138570496. For the stock, the TTM Price-to-Sale (P/S) ratio is 2740.77. Its current Enterprise Value per Revenue stands at 14981.191 whereas that against EBITDA is -6.584.
Stock Price History:
The Beta on a monthly basis for PROK is 1.59, which has changed by -0.72361624 over the last 52 weeks, in comparison to a change of 0.042615533 over the same period for the S&P500. Over the past 52 weeks, PROK has reached a high of $4.44, while it has fallen to a 52-week low of $0.46. The 50-Day Moving Average of the stock is -28.09%, while the 200-Day Moving Average is calculated to be -56.87%.
Shares Statistics:
It appears that PROK traded 676.18K shares on average per day over the past three months and 1464630 shares per day over the past ten days. A total of 128.05M shares are outstanding, with a floating share count of 92.44M. Insiders hold about 28.64% of the company’s shares, while institutions hold 44.20% stake in the company. Shares short for PROK as of 1743379200 were 11927193 with a Short Ratio of 17.64, compared to 1740700800 on 11933117. Therefore, it implies a Short% of Shares Outstanding of 11927193 and a Short% of Float of 13.120000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of ProKidney Corp (PROK) reflects the combined expertise of 3.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.14 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.52 and -$0.72 for the fiscal current year, implying an average EPS of -$0.6. EPS for the following year is -$0.6, with 5.0 analysts recommending between -$0.46 and -$0.82.
